Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal dominant intermediate Charcot-Marie-Tooth disease type B is a rare hereditary motor and sensory neuropathy characterized by intermediate motor median nerve conduction velocities (usually between 25 and 45 m/s) and signs of both demyelination and axonal degeneration in nerve biopsies. It presents with mild to moderately severe, slowly progressive usual clinical features of Charcot-Marie-Tooth disease (muscle weakness and atrophy of the distal extremities, distal sensory loss, reduced or absent deep tendon reflexes, and feet deformities). Other findings include asymptomatic neutropenia and early-onset cataracts.
Features include always present findings: Distal amyotrophy and Distal muscle weakness; and sometimes findings: Segmental peripheral demyelination. 12 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 1 | Hyporeflexia |
Muscles | 1 | Distal muscle weakness |
DNM2 encodes dynamin 2 (870 aa). Catalyzes the hydrolysis of GTP and utilizes this energy to mediate vesicle scission at plasma membrane during endocytosis and filament remodeling at many actin structures during organization of the actin cytoskeleton. Highest expression in Lung (107.7 TPM) and Skin Sun Exposed Lower leg (97.2 TPM).
Charcot-Marie-Tooth disease dominant intermediate B is associated with mutations in the DNM2 gene on chromosome 19.
DNM2 is classified as a druggable target (Clinically Actionable, Enzyme, and Transporter categories) with score 4.4.
Genetic testing for DNM2 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 2 always present features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Charcot-Marie-Tooth disease dominant intermediate B.
5 publications have been identified in PubMed for Charcot-Marie-Tooth disease dominant intermediate B. Research spans Basic Science / Preclinical (40%), Review / Meta-Analysis (20%), and Case Report / Case Series (20%).
Goret M (2026). [PMID: 41683892](https://pubmed.ncbi.nlm.nih.gov/41683892/). *Int J Mol Sci*. [Basic Science / Preclinical]
Rimoldi M (2025). [PMID: 40259930](https://pubmed.ncbi.nlm.nih.gov/40259930/). *Front Genet*. [Case Report / Case Series]
Cashman CR (2025). [PMID: 40400204](https://pubmed.ncbi.nlm.nih.gov/40400204/). *Ann Clin Transl Neurol*. [Review / Meta-Analysis]
Goret M (2025). [PMID: 40042903](https://pubmed.ncbi.nlm.nih.gov/40042903/). *Proc Natl Acad Sci U S A*. [Gene Therapy / Novel Therapeutics]
Ferreira T (2024). [PMID: 38549004](https://pubmed.ncbi.nlm.nih.gov/38549004/). *J Neurol*. [Basic Science / Preclinical]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 3:00 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease dominant intermediate B